Cornerstone Therapeutics of Cary became Chiesi USA on Monday, finalizing a $300 million acquisition by Italian drug maker Chiesi Farmaceutici.

The name change makes Cornerstone a wholly-owned subsidiary of Chiesi, previously a majority owner of the Cary specialty drug company.

The company has 64 employees in Cary; Chiesi employs about 4,000 worldwide.

Chiesi USA specializes in commercializing drugs for hospital use and other specialty markets. The company was created in 2008 when Cary’s Cornerstone BioPharma acquired Critical Therapeutics of Boston. Chiesi became a majority owner in 2009.

Chiesi USA also focuses on acquiring other drug developers and marketing generic drugs through its own subsidiary, Aristos Pharmaceuticals.

Staff writer John Murawski

Join the Discussion

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Terms of Service